Business Context and Reporting Period
Company: Moleculin Biotech, Inc. (MBRX)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: Moleculin is a clinical-stage pharmaceutical company focused on developing Annamycin (naxtarubicin), a next-generation anthracycline, for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). The company is currently conducting the pivotal Phase 2B/3 "MIRACLE" trial. It also maintains portfolios for WP1066 (immune modulators) and WP1122 (glycolysis inhibitors). The company has no manufacturing facilities or sales organization and relies on third-party contractors and potential strategic partners.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(12.8) million | $(5.9) million |
| Net Loss Available to Common Stockholders | $(14.6) million | $(5.9) million |
| Net Loss Per Share (Basic & Diluted) | $(3.54) | $(15.80) |
| Operating Expenses | $7.9 million | $5.9 million |
| Cash and Cash Equivalents (End of Period) | $10.3 million | $7.7 million |
| Net Cash Used in Operating Activities | $(6.1) million | $(4.6) million |
| Net Cash Provided by Financing Activities | $7.6 million | $8.0 million |
| Total Assets | $23.4 million | $22.1 million |
| Total Liabilities | $8.2 million | $7.1 million |
| Stockholders' Equity | $15.2 million | $15.0 million |
Note: The company reported no revenue for either period. The significant increase in net loss for Q1 2026 is primarily driven by a $15.2 million loss on the issuance of warrant liabilities, partially offset by a $10.8 million gain from the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Operating Expenses: Increased by $1.9 million to $7.9 million. Research and Development (R&D) expenses rose by $2.0 million (from $3.4M to $5.4M), primarily due to the MIRACLE clinical trial in Europe ($1.4M) and additional nonclinical studies.
- Warrant Activity: In February 2026, the company entered into warrant inducement agreements. Holders exercised warrants for 2.1 million shares (gross proceeds ~$8.3M), and the company issued new Series H warrants. This resulted in a $15.2 million loss on issuance and a $10.8 million gain from fair value changes, significantly impacting the bottom line compared to Q1 2025 which had no such activity.
- Capital Structure: The company completed a 1-for-25 reverse stock split on December 1, 2025. Outstanding shares increased from 3.2 million (Dec 31, 2025) to 5.3 million (March 31, 2026) due to warrant exercises and inducements.
- Liquidity: Cash balance increased by $1.4 million to $10.3 million, driven by financing proceeds of $7.6 million offset by operating cash burn of $6.1 million.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Milestones: The company expects the first unblinding of data from the MIRACLE trial (45 subjects) to occur in mid-2026. Preliminary blinded data shows a composite complete remission rate exceeding 40% and a complete remission rate of approximately 30%.
- Capital Needs: Management states that cash on hand ($10.3M) plus subsequent ATM proceeds ($0.8M) is sufficient to fund operations into the third quarter of 2026. The company estimates a need for approximately $25 million in additional funding to support the MIRACLE trial and operations into Q1 2027.
- Subsequent Events: In May 2026, the company sold 354,757 shares under its ATM agreement for net proceeds of ~$0.8 million. The lowest sale price ($2.01) triggered a reset of Series G and H warrant exercise prices from $2.40 to $2.01.
Risks and Contingencies
- Going Concern: The filing includes a substantial doubt disclosure regarding the company's ability to continue as a going concern due to an accumulated deficit of $218.8 million and insufficient cash to fund operations for the next 12 months without additional financing.
- Nasdaq Compliance: The company previously faced delisting risks regarding stockholders' equity and bid price rules but regained compliance in late 2025. Continued compliance is not guaranteed.
- Dilution Risk: Future equity financings may trigger downward adjustments to the exercise prices of outstanding Series G and H warrants, leading to significant dilution.
Investor Verification Checklist
- Runway Validation: Verify the sufficiency of the $10.3 million cash balance against the projected $25 million funding gap to reach Q1 2027.
- Warrant Dilution: Assess the impact of the recent warrant exercise price reset (to $2.01) and the potential for further resets if future financing occurs below this price.
- Clinical Data Readout: Monitor the mid-2026 interim unblinding of the MIRACLE trial data, which is critical for future valuation and partnership opportunities.
- Financing Terms: Review the terms of any upcoming equity offerings, specifically looking for "down-round" provisions that could further dilute existing shareholders.
- Regulatory Status: Confirm continued compliance with Nasdaq listing requirements, given the company's recent history of deficiencies.